Therapeutic Utility of Phosphodiesterase Type I Inhibitors in Neurological Conditions

Frontiers in Neuroscience - Switzerland
doi 10.3389/fnins.2011.00021
Full Text
Abstract

Available in full text

Categories
Neuroscience
Date
Authors
Publisher

Frontiers Media SA

Related search

AB030. Evolution of Phosphodiesterase Type 5 Inhibitors

Translational Andrology and Urology
Reproductive MedicineUrology
2016English

Phosphodiesterase Type 5 Inhibitors in the Treatment of Pulmonary Arterial Hypertension

Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology
2010English

Phosphodiesterase Type 5 Inhibitors: A Biochemical and Clinical Correlation Survey

International Journal of Impotence Research
Urology
2003English

Daily Use of Phosphodiesterase Type 5 Inhibitors as Prevention for Recurrent Priapism

Revista da Associacao Medica Brasileira
Medicine
2017English

Phosphodiesterase Inhibitors in Vascular Ischemia: A Case Report and Review of Their Use in Ischemic Conditions

Canadian Journal of Plastic Surgery
2010English

Study of Angiogenesis-Related Phosphodiesterase Inhibitors

Journal of Applied Pharmaceutical Science
MedicineToxicologyPharmaceuticsPharmacology
2015English

Synthesis and Biological Evaluation of the First Dual Tyrosyl-Dna Phosphodiesterase I (Tdp1)–Topoisomerase I (Top1) Inhibitors

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2012English

Quantitative Risk-Benefit Analysis of Oral Phosphodiesterase Type 5 Inhibitors on Erectile Dysfunction Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Tyrosyl-Dna Phosphodiesterase 1 (Tdp1) Inhibitors

Expert Opinion on Therapeutic Patents
MedicineDrug DiscoveryPharmacology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy